Drug Trial Radar · NCT06428903
Comparative Bioavailability Study of Tablet and Granule Formulations of ADC189 and the Study of Ultra-high Dose
Last checked: Nov 19, 2026Latest source record: Jan 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Mar 12, 2024
Primary completion
Sep 22, 2024
Study completion Sep 22, 2024
Sponsor
- Lead sponsor
- Jiaxing AnDiCon Biotech Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- May 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Part 1 of this study will compare the pharmacokinetic performance of tablet and granule formulations of ADC189 under fasted conditions in healthy volunteers. A randomized, two-period, two-treatment crossover design is used. In each period, each volunteer will receive a single oral dose of the tablet or granule formulation without food. The purpose of Part 2 study is to determine the safety and pharmacokinetics of ultra high dose of ADC189 in healthy subjects.
Conditions
- Healthy Volunteer
Interventions
ADC189 tabletDrug
ADC189 tablet, 45 mg, single oral dose in each Group. (Part 1 study)
ADC189 granulesDrug
ADC189 granules, 45 mg, single oral dose in each Group. (Part 1 study)
ADC189 180mgDrug
ADC189 tablet, 180 mg, single oral dose. (Part 2 study)
Primary outcomes
What the sponsor says the trial is designed to measure.
- ADC189 GranulesTime frame: 15 days
- ADC189 TabletTime frame: 15 days
- ADC189 Ultra high doseTime frame: 15 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhao Wei
Jinan, Shang Dong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.